Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Lantus is the world's number-one selling insulin brand in terms of both sales and units (source: IMS, 2011 sales) and is available in over 70 countries worldwide.
Made by Paris-based Sanofi (SNY), it dominates some 80% of the long-acting insulin market and, according to Sanofi, is used by 7 million patients in the world. Sanofi's Lantus is injected once daily. The injection is administered using syringes or specific pens including Lantus SoloStar, which is a pre-filled disposable pen, or the newer ClikStar, which is a reusable insulin pen.
Eli Lilly (LLY) is planning to challenge Sanofi's almost 10-year dominance with its own insulin glargine product called LY2963016, now in phase 3 testing (Trials called Element 1 and Element 2).
http://seekingalpha.com/article/910881-eli-lilly-and-the-state-of-the-insulin-battle
Made by Paris-based Sanofi (SNY), it dominates some 80% of the long-acting insulin market and, according to Sanofi, is used by 7 million patients in the world. Sanofi's Lantus is injected once daily. The injection is administered using syringes or specific pens including Lantus SoloStar, which is a pre-filled disposable pen, or the newer ClikStar, which is a reusable insulin pen.
Eli Lilly (LLY) is planning to challenge Sanofi's almost 10-year dominance with its own insulin glargine product called LY2963016, now in phase 3 testing (Trials called Element 1 and Element 2).
http://seekingalpha.com/article/910881-eli-lilly-and-the-state-of-the-insulin-battle